Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present quality ...

February 10-11: BIO CEO & Investor Conference 2025. Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will participate in one-on-one meetings at this conference, taking place in New York.

The Massachusetts protest against Trump and Project 2025 is scheduled at noon near the State House building on Beacon Street ...

Stifel raised the firm’s price target on Boston Scientific (BSX) to $120 from $115 and keeps a Buy rating on the shares after having hosted ...

The basement of the Northeastern University Catholic Center in Boston on the night of Jan. 23 looked like any other college ...

The Cleveland Cavaliers' matchup against the Boston Celtics was already a must ... and put Celtics forward Kristaps Porziņģis on a poster with a highlight jam. The best part of this play was ...

Boston Scientific (NYSE:BSX – Get Free Report) had its price objective lifted by equities research analysts at Raymond James ...

For the current quarter ending in March, Boston Scientific expects its per-share earnings to range from 66 cents to 68 cents. The company expects full-year earnings in the range of $2.80 to $2.87 per ...

Stifel analysts increased their price target on Boston Scientific Corporation (NYSE:BSX) shares from $115.00 to $120.00, while reiterating a Buy rating for the medical device company. The adjustment ...

Feb 5 (Reuters) - Medical device maker Boston Scientific (BSX.N), opens new tab forecast annual profit above Wall Street estimates on Wednesday, banking on steady demand for its heart devices.

Boston Scientific Corporation (NYSE:BSX), a leading player in the medical technology sector, has been making waves in the industry with its innovative product pipeline and strong market performance.